Kyverna Therapeutics (KYTX) Expected to Announce Quarterly Earnings on Monday

Kyverna Therapeutics (NASDAQ:KYTX) is expected to announce its Q2 2025 earnings results before the market opens on Monday, August 11th. Analysts expect the company to announce earnings of ($1.00) per share for the quarter.

Kyverna Therapeutics (NASDAQ:KYTX) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($1.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.21) by $0.18. On average, analysts expect Kyverna Therapeutics to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Kyverna Therapeutics Stock Performance

Shares of KYTX opened at $3.24 on Friday. The stock has a market capitalization of $140.03 million, a PE ratio of -0.96 and a beta of 3.05. The company’s 50-day simple moving average is $3.40 and its 200-day simple moving average is $2.80. Kyverna Therapeutics has a 1 year low of $1.78 and a 1 year high of $8.78.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in KYTX. Rhumbline Advisers grew its holdings in Kyverna Therapeutics by 22.0% during the 1st quarter. Rhumbline Advisers now owns 31,614 shares of the company’s stock worth $61,000 after acquiring an additional 5,694 shares in the last quarter. Bank of America Corp DE grew its holdings in Kyverna Therapeutics by 41.6% during the 4th quarter. Bank of America Corp DE now owns 21,788 shares of the company’s stock worth $81,000 after acquiring an additional 6,400 shares in the last quarter. Cubist Systematic Strategies LLC grew its holdings in Kyverna Therapeutics by 31.1% during the 1st quarter. Cubist Systematic Strategies LLC now owns 68,628 shares of the company’s stock worth $132,000 after acquiring an additional 16,267 shares in the last quarter. Finally, AQR Capital Management LLC purchased a new position in shares of Kyverna Therapeutics in the 1st quarter valued at about $137,000. Institutional investors and hedge funds own 18.08% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright upgraded Kyverna Therapeutics from a “neutral” rating to a “buy” rating and lifted their target price for the company from $4.00 to $5.00 in a report on Tuesday, May 27th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $15.60.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.